Allogene Therapeutics Inc
NASDAQ:ALLO

Watchlist Manager
Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc
NASDAQ:ALLO
Watchlist
Price: 1.35 USD
Market Cap: 303.4m USD

P/E
Price to Earnings

-1.4
Current
-1.4
Median
23.5
Industry
Higher than median
Lower than industry value

The Price to Earnings (P/E) ratio shows how much investors are willing to pay for each dollar of a company’s earnings. It’s calculated by dividing the company’s market value by its net income.

P/E
-1.4
=
Market Cap
301.3m USD
/
Net Income
-212m USD
All Countries
Close
Earnings Growth PEG
US
Allogene Therapeutics Inc
NASDAQ:ALLO
Average P/E: 207.4
Negative Multiple: -1.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 957.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 575 047.8 N/A N/A
AU
CSL Ltd
ASX:CSL
18.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 171.5
N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-1.4
2-Years Forward
P/E
-1.5
3-Years Forward
P/E
-1.6